Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.54 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
| ▸ | PRMT6 | Q96LA8 | 5/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12305657 | 0.88 | PRMT6 (0.62) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| SCHEMBL1697126 | 0.84 | MAPT (0.64) | CYP3A4PKMKDM4EMAPTLMNA | |
| SCHEMBL6720486 | 0.83 | CYP3A4 (0.60) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| SCHEMBL9416529 | 0.82 | SLC2A4 (0.75) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| Hydrochloric Acid SCHEMBL3273205 | 0.81 | MAPT (0.68) | CYP3A4PKMKDM4EMAPTKMT2A | |
| SCHEMBL6898308 | 0.80 | CYP3A4 (0.67) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| SCHEMBL24465862 | 0.80 | NOS1 (0.57) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| SCHEMBL1041003 | 0.79 | SLC2A4 (0.61) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| SCHEMBL2307498 | 0.79 | TAAR1 (0.61) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| SCHEMBL12305656 | 0.79 | PRMT6 (0.65) | CYP3A4KDM4EMAPTKMT2ANOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139308-B1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| CN-112552274-B | Xanthone compound and preparation method and application thereof | 江西中医药大学 | 2022-11-18 | — | — | CN | disclosed |
| US-20220152072-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2022-05-19 | — | — | US | disclosed |
| CN-109053523-B | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-112552274-A | Xanthone compound and preparation method and application thereof | 江西中医药大学 | 2021-03-26 | — | — | CN | disclosed |
| CN-111643496-A | Methods of using MEK inhibitors | 埃克塞利希斯股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS, INC. | 2020-01-30 | — | — | US | disclosed |
| CN-110668988-A | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| CN-1946391-A | Combinations comprising alpha-2-delta ligands | PFIZER PROD INC (US) | 2007-04-11 | — | — | CN | disclosed |
| US-20060063766-A1 | Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. | 2006-03-23 | — | — | US | disclosed |
| US-20060052378-A1 | Psychological disorders; analgesics; eating disorders; drug abuse; 4-(8-chloro-naphthalen-2-yl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; 7-(6-methoxy-pyrazin-2yl)-2-methyl-4-(naphthalene-2-yl)-1,2,3,4-tetrahydroisoquinoline; treating amide intermediates with sodium borohydride | CURIA GLOBAL, INC. | 2006-03-09 | — | — | US | disclosed |
| WO-2006020049-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-5234946-A | Anticholesterol, antilipemic | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-10 | — | — | US | disclosed |
| EP-0318860-B1 | SUBSTITUTED ALKYLAMINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-06-16 | — | — | EP | disclosed |
| EP-0395768-A1 | SUBSTITUTED ALLYLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-11-07 | — | — | EP | disclosed |
| CN-1042910-A | The allylamine derivatives that replaces, their production method and application thereof | BANYU PHARMA CO LTD (JP) | 1990-06-13 | — | — | CN | disclosed |
| CN-1037141-A | The alkylamine derivative that replaces | BANYU PHARMA CO LTD (JP) | 1989-11-15 | — | — | CN | disclosed |
| EP-0318860-A2 | Substituted alkylamine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063766-A1 | Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin | SLC6A3, SLC6A4, SLC6A2 | CYP3A4 100/4885CYP1A2 147/4885PKM 3610/4885 |
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | BRAF, NRAS, MAP3K20 | CYP3A4 1209/4885CYP1A2 1175/4885PKM 560/4885 |
| US-20060052378-A1 | Psychological disorders; analgesics; eating disorders; drug abuse; 4-(8-chloro-naphthalen-2-yl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; 7-(6-methoxy-pyrazin-2yl)-2-methyl-4-(naphthalene-2-yl)-1,2,3,4-tetrahydroisoquinoline; treating amide intermediates with sodium borohydride | OPRK1, OPRL1, OPRD1 | CYP3A4 488/4885CYP1A2 196/4885PKM 2920/4885 |
| US-20220152072-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | CYP3A4 3488/4885CYP1A2 3711/4885PKM 581/4885 |
| US-11597699-B2 | MEK inhibitors and methods of their use | BRAF, NRAS, MAP3K20 | CYP3A4 1209/4885CYP1A2 1175/4885PKM 560/4885 |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, MAP3K20 | CYP3A4 1209/4885CYP1A2 1175/4885PKM 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.